MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive: Pretreatment of the cells for 1.5 h with compounds 1, 2, 3, 4, 5, 9, 10, 11, and 13, 1 μM, resulted in significant suppression of CML-AGE-mediated phospho/total ERK1/2.